

- Plasma cell leukemia, 715
 Plasmacytic lymphoma of the oral cavity, 1270
 Plasmacytoid T dendritic cells, 372e-6, 372e-7t.
See also Dendritic cells
 Plasmacytoma, 715, 715t
 Plasma exchange/plasmapheresis
 for cerebellar degeneration, 618
 for chronic inflammatory demyelinating polyneuropathy, 2699
 for Guillain-Barré syndrome, 2697
 for hemolytic-uremic syndrome, 1864
 for monoclonal gammopathy of undetermined significance, 716
 for MS, 2667
 for myasthenia gravis, 2705
 for neuromyelitis optica, 2673
 for neuromyotonia, 619
 for pemphigus vulgaris, 371
 for thrombotic thrombocytopenic purpura, 729-730, 1864
 for Waldenström's macroglobulinemia, 718
 Plasma protein binding, 35
 Plasma renin activity, 306
 Plasma vasopressin, in diabetes insipidus, 295
 Plasmin, 402f, 403, 758, 758f
 Plasminogen, 402, 402f, 758, 758f
 Plasminogen activator, 758, 758f
 Plasminogen activator inhibitor I (PAI-1)
 arterial thrombotic disease and, 744
 in endothelial cells, 265e-2
 in fibrinolysis, 758, 758f
 in metabolic syndrome, 744
 Plasminogen activator inhibitors, 402f, 403
Plasmodium spp. *See also* Malaria
 characteristics of, 250e-1, 250e-1t, 1369t
 drug resistance in, 1370f, 1379, 1381f, 1384
 entry into host, 145e-1
 epidemiology of, 245e-4t
 host response to, 1371-1672
 laboratory identification of
 blood findings, 1375-1377, 1377t
 demonstration of parasite, 245e-4t, 245e-6t, 250e-2-4f, 1375-1377f, 1375-1378, 1377t
 PCR, 245e-3
 life-cycle hosts of, 245e-4t
P. falciparum
 adherence of, 145e-2t
 characteristics of, 250e-1t, 1369, 1369t
 erythrocyte changes caused by, 1371
 geographic distribution of, 1370-1371
 laboratory identification of, 250e-2f, 250e-3f, 1375f, 1376, 1376f, 1377t
 ligand-receptor interactions of, 1371
 temperature sensitivity of, 1371
P. knowlesi
 characteristics of, 1369
 geographic distribution of, 1370-1371
 laboratory identification of, 245e-3
P. malariae
 characteristics of, 250e-1t, 1369, 1369t
 geographic distribution of, 1370-1371
 laboratory identification of, 250e-3f, 250e-4f, 1377f
P. ovale
 characteristics of, 250e-1t, 1369t
 geographic distribution of, 1370
 laboratory identification of, 250e-3f, 250e-4f, 1377f
P. vivax
 adherence of, 145e-2t, 145e-3
 characteristics of, 250e-1t, 1369t
 geographic distribution of, 1370-1371
 host receptors for, 138e-2, 1369
 laboratory identification of, 250e-2f, 250e-3f, 1376f
 resistance to, 145e-3
 temperature sensitivity of, 1371
 transmission cycle, 145e-10, 1369f
 Plasticity, of cancer cells, 102e-12
 Plateau pressure, 1733
 Platelet(s), 725
 abnormal function of, 368
 activation of, 275f, 276, 400-401, 725, 741f, 742, 746f
 adhesion of, 275-276, 400-401, 725, 741-742, 745, 746f
 aggregation of, 276, 725, 742, 746f
 in AML, 681, 685
 in arterial thrombosis, 275-276, 741-742
 characteristics of, 275, 725, 741
 disorders of, 403t, 725
 acquired, 730
 hemolytic-uremic syndrome. *See* Hemolytic-uremic syndrome (HUS)
 inherited, 730
 thrombocytopenia. *See* Thrombocytopenia
 thrombocytosis. *See* Thrombocytosis
 von Willebrand disease. *See* von Willebrand disease
 elevated levels of, 677, 678
 giant, 81e-1, 81e-6f
 hematopoietic differentiation of, 89e-3f
 in hemostasis, 400-401, 725
 in inflammation, 276-277, 742
 in peripheral blood smear, 81e-1
 reference values for, 2756t
 in shock, 1747
 transfusion of. *See* Platelet transfusion
 Platelet-activating factor, 372e-15t, 1746
 Platelet aggregometry, 407
 Platelet count
 in DIC, 737
 normal, 404, 725
 in preoperative evaluation, 404
 Platelet-derived growth factor (PDGF), 102e-14, 102e-15f, 372e-14, 372e-14t
 Platelet-derived growth factor (PDGF) receptors, 102e-15f, 119e-1, 599
 Platelet emboli, retinal, 40e-4
 Platelet factor 4 (PF-4), 372e-13t, 727, 750
 Platelet function tests, 407
 Platelet inhibitors. *See* Antiplatelet agents
 Platelet plug, 400-401, 725
 Platelet-rich plasma, 138e-2
 Platelet transfusion
 for aplastic anemia, 667
 characteristics of, 138e-2t, 138e-3
 for coagulation disorders in liver disease, 739
 corrected count increment, 138e-3
 for DIC, 738
 refractoriness to, 138e-3
 response to, 138e-2t, 138e-3
 single-donor apheresis for, 138e-2
 for thrombocytopenia, 103e-24
 Platybasia, 426e-2
 Platypnea, 47e-3, 1992
 Platypus, 2740-2741
 PLC γ -associated antibody deficiency and immune dysregulation (PLAID), 2113
 Pleconaril, 1203, 1293
Pleistophora spp., 1408
 Pleomorphic adenoma, 241
 Pleomorphic xanthoastrocytomas, 601
 Plerixafor, 89e-1, 139e-2
 Pleural effusion, 1716
 in chylothorax, 1718
 in cirrhosis, 1717
 diagnosis of, 308e-14f, 1717f, 1725
 differential diagnosis of, 1718-1719, 1718t
 dyspnea in, 47e-2
 etiology of, 47e-4, 1716
 exudative, 1716
 in heart failure, 1725-1726
 in hemothorax, 1718
 malignant, 474, 510, 512, 1717
 in mesothelioma, 1717
 in pancreatitis, 2092, 2095f
 parapneumonic, 1717
 in pulmonary embolism, 1717
 transudative, 1716
 tuberculous, 1109-1110, 1718
 in viral infection, 1718
 Pleural (primary) effusion lymphoma, 214e-7, 1194
 Pleuritis
 abdominal pain in, 105
 chest pain in, 96t, 98, 99
 in rheumatoid arthritis, 2138
 in SLE, 2129, 2129t
 tuberculous, 1718
 Pleurodynia (Bornholm disease), 1291
 Plexopathies
 brachial. *See* Brachial plexopathy
 evaluation and treatment of, 2694
 lumbosacral, 2693-2694, 2694t
 perioperative, 2693
 radiation-induced, 2694
 PLP (pyridoxal 5'-phosphate), 426e-5
 PLTP (phospholipid transfer protein), 2438
 Plummer-Vinson syndrome, 237, 532
 Pluripotent stem cells, 454, 454f
 Plutonium exposure, 263e-3t, 263e-6t, 263e-7
 PML. *See* Progressive multifocal leukoencephalopathy (PML)
 PML gene, 679
 PML-RARA, 679, 687
 PML-RAR gene mutations, 102e-7, 431t
 PMNs (polymorphonuclear leukocytes), 150e-1, 1601
 PMP22 gene mutations, 434
 PMS1 gene mutations, 101e-6t, 596
 PMS2 gene mutations, 101e-6t, 592, 596
 PNad (peripheral node addressin), 372e-26
 PNAG, 145e-10
 pNETs. *See* Pancreatic neuroendocrine tumors (pNETs)
 pNETs (primitive neuroectodermal tumors), 119e-4. *See also* Ewing's sarcoma
 Pneumatic compression device, for VTE prophylaxis, 55
 Pneumatosis intestinalis, 1979, 2162
 Pneumococcal H inhibitor (hic), 947
 Pneumococcal infections, 946
 approach to the patient, 950
 in cancer patient, 484, 484t, 486t
 case-fatality ratios for, 949-950
 endocarditis, 817t, 823. *See also* Infective endocarditis
 epidemiology of, 947-949, 948f, 949f
 epiglottitis, 234-235
 etiology of, 946-947. *See also* *Streptococcus pneumoniae*
 global considerations in, 949
 in HIV infection, 1250
 host defense mechanisms, 950
 incidence pre- and postvaccine, U.S., 785t, 949f, 953, 953f
 mastoiditis, 231
 meningitis. *See* Meningitis
 otitis media. *See* Otitis media
 pathogenesis of, 949-950
 pneumonia. *See* Pneumonia, bacterial
 postsplenectomy, 413
 prevention of, 952-953. *See also* Pneumococcal vaccine
 risk factors for, 949, 949t
 seasonal variations in, 949
 sinusitis, 226, 952
 treatment of, 940t, 952-953
 in ventilator-associated pneumonia, 915
 Pneumococcal surface adhesion A, 947
 Pneumococcal surface antigen A, 947f
 Pneumococcal surface protein A, 947f
 Pneumococcal surface protein C, 947, 947f
 Pneumococcal vaccine
 capsular polysaccharide, 953-954
 genomics and, 778
 global considerations in, 947
 polysaccharide-protein conjugate, 949f, 953, 953f
 recommended administration of
 in adults, 29t, 787-788f, 809
 after splenectomy, 413, 635
 in cancer patients, 485t, 492
 in elderly, 84
 in HIV infection, 798, 1252-1253t
 in liver disease, 1995
 in transplant recipients, 929, 929t
 in travelers, 794
Pneumocystis jiroveci, 372e-26, 765t, 1358. *See also* *Pneumocystis pneumonia* (PCP)